MHRA-100065-PIP01-21-M01 (update)

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
Invented Name
  • Brilique
  • Brilique
  • Brilique
  • Brilique
PIP Number MHRA-100065-PIP01-21-M01 (update)
Pharmaceutical form(s)
  • Tablet
  • Film-coated tablet
  • Orodispersible tablet
Therapeutic area
  • Cardiovascular Diseases
  • Haematology-Hemostaseology
Conditions / Indications
Conditions / Indications:
  • Prevention of thromboembolic events
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance opinion date
Compliance Check Procedure Number
Compliance procedure number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):TICAGRELOR.pdf
Published Date 03/11/2021